The accompanying Consolidated Balance Sheet as of September 30, 2018 was derived from the audited annual consolidated financial statements as of the period then ended.
In the fourth quarter of fiscal year 2018, the Company entered into a definitive agreement to sell its semiconductor cryogenics business to Edwards Vacuum LLC (a member of the Atlas Copco Group), (the “Disposition”).
The Company determined that the semiconductor cryogenics business met the “held for sale” criteria and the “discontinued operations” criteria in accordance with Financial Accounting Standard Boards (“FASB”) Accounting Standards Codification (“ASC”) 205, Presentation of Financial Statements, (“FASB ASC 205”) as of September 30, 2018.
The Consolidated Balance Sheets and Consolidated Statements of Operations, and the notes to the Consolidated Financial Statements were restated for all periods presented to reflect the discontinuation of the semiconductor cryogenics business, in accordance with FASB ASC 205.
As part of this amendment, liabilities assumed by the purchaser were revised to include accounts payable related to the semiconductor cryogenics business.
As of September 30, 2018, the Company has revised its accounts payable balance on a continuing operations basis to exclude accounts payable related to the semiconductor cryogenics business and revised its current liabilities held for sale balance to include accounts payable related to the semiconductor cryogenics business on its Consolidated Balance Sheets.
As of September 30, 2018, the accounts payable balance related to the semiconductor cryogenics business was $11.1 million.
During the three months ended March 31, 2019, the Company identified a misclassification related to the presentation of the product and service revenue and the cost of product and service revenue related to the GENEWIZ Group (“GENEWIZ”) in the Company's Consolidated Statements of Operations for the three months ended December 31, 2018. service revenue line items in the Consolidated Statements of Operations in the Quarterly Report on Form 10-Q for the three months ended December 31, 2018.
GENEWIZ was acquired during the three months ended December 31, 2018 and therefore the misclassification did not impact any other historical periods.
Net foreign currency transaction and remeasurement losses totaled $0.5 million and $0.6 million, respectively, during the three months ended June 30, 2019 and 2018 and $1.1 million and $3.1 million, respectively, during the nine months ended June 30, 2019 and 2018.
As of June 30, 2019, the Company had no assets or liabilities measured and recorded at fair value on a recurring basis using Level 3 inputs.
The amendments in ASU 2019-05 allow entities to elect the fair value option on certain financial instruments.This section provides an analysis of our financial results for the three and nine months ended June 30, 2019 compared to the three and nine months ended June 30, 2018.
In the life sciences sample-based services market, we utilize our core competencies and capabilities in automation and cryogenics to provide comprehensive bio-sample management solutions to a broad range of end markets within the life sciences industry.
Please refer to Note 5, “Acquisitions” in the Notes to the unaudited consolidated financial statements included in Item 1 "Consolidated Financial Statements" of this Quarterly Report on Form 10-Q for further information on these transactions.
Results of Operations - Revenue for the three months ended June 30, 2019 increased to $203.9 million, or by 18%, as compared to the corresponding period of the prior fiscal year.
Gross margin was 41.0% for the three months ended June 30, 2019 as compared to 38.8% for the corresponding period of the prior fiscal year, an increase of $16.7 million.
Operating expenses were $67.1 million during the three months ended June 30, 2019 as compared to $54.3 million during the corresponding period of the prior fiscal year, an increase of $12.8 million.